The listing of traders backing little-known life sciences fund Catalio Capital reads like a roll name of personal fairness and hedge fund titans. Amongst them: Thoma Bravo’s Orlando Bravo, Brevan Howard’s Alan Howard, Stanley Druckenmiller and KKR’s Henry Kravis.
How a tiny biotech enterprise capital fund led by 33-year-old managing companion George Petrocheilos attracted such a kaleidoscope of finance luminaries is a narrative of equal elements hustle, chutzpah and connections.
It has not harm that the daddy of Petrocheilos’s co-founder Jacob Vogelstein is a famed geneticist who has allowed his son’s agency to incubate corporations bearing a few of his most promising concepts in most cancers remedy. Petrocheilos’s pater and mitera have been additionally early-stage traders in Catalio, whose identify is the Greek phrase for “catalyse,” or velocity up.
No matter how Catalio amassed capital or marshalled sources, the agency’s work is paying off: It has returned greater than $300mn to its restricted companions in recent times, a uncommon feat in a troublesome market.
“This man will name anyone — that’s the sweetness about him,” Kravis stated of Petrocheilos in an interview. “There isn’t any one he received’t communicate to. It’s superb how many individuals he has gotten to know through the years who adore him. They’ve given him cash and so they proceed to present him extra money.” KKR just lately bought a minority stake within the group, its first funding in an early-stage life sciences investing fund.
Led by its relentlessly networking Greek-born managing companion Petrocheilos and his co-founder Vogelstein, a scientist who met Petrocheilos whereas learning at Johns Hopkins College, Catalio has engineered 20 exits because it was based 4 years in the past. Its property beneath administration have topped $1.3bn, a speedy ascent in a sector that has struggled to draw new capital in recent times.
Vogelstein performs the position of the “quiet and good” knowledgeable “digging into the science of investments”, whereas Petrocheilos is the networker and fundraiser with “extra power than an Energizer bunny,” in line with Kravis, who serves as Catalio’s chair.
Catalio has managed to journey out a uneven few years within the biotech VC trade, wherein companies have struggled towards rising rates of interest and a scarcity of capital accessible to biotechnology corporations spending closely to develop merchandise with unsure monetary prospects.
Petrocheilos was launched to Kravis by KKR’s now co-chief government Joseph Bae, who Petrocheilos first impressed over a 15-minute espresso as a college scholar. Bae provided an internship; as a substitute Petrocheilos requested Bae to vow to have lunch with him annually.
“I get many nos,” stated Petrocheilos in an interview from Catalio’s workplace in New York’s Chelsea neighbourhood. “No at present means no at present, it doesn’t imply no tomorrow. Asking one other time and one other time is free.” Petrocheilos’s ambition has helped Catalio break into the clubby world of early-stage life science investing, which is dominated by enterprise capitalists in San Francisco and Cambridge, Massachusetts.
Alongside Petrocheilos’s hustle, Catalio’s different “secret sauce”, Kravis stated, got here from Vogelstein’s father, Bert, a famed Johns Hopkins researcher, who helped the agency assemble a roster of 45 main scientists, together with a number of Nobel Prize winners, to advise on potential investments.
The older Vogelstein’s laboratory has been the supply of 5 of the 75 corporations wherein Catalio has invested, together with its largest exit up to now: most cancers diagnostics firm Thrive, which was purchased by Precise Sciences for as much as $2.1bn. Vogelstein stated he “by no means” anticipated to enter enterprise along with his son.
“Jacob clearly has the technical and scientific expertise that George doesn’t,” stated Vogelstein. “George has a considerable amount of contacts that he’s met, though he’s younger . . . that he has acquired each by way of his household and his personal doing, which has been very worthwhile. They appear to be a great pair.”
Johns Hopkins has additionally confirmed to be a worthwhile community. The agency was first backed by Philippe Laffont, the billionaire founding father of hedge fund Coatue Administration and the daddy of a classmate of Petrocheilos and Vogelstein. Laffont, whose son briefly labored at Catalio, then made introductions throughout the hedge fund trade earlier than finally promoting his stake.
KKR’s funding into Catalio is the newest in a succession of offers whereby personal fairness companies, together with Blackstone, Apollo and Carlyle, which generally put money into massive suppliers to the pharmaceutical trade, have purchased stakes in biotech enterprise capital companies making riskier bets on novel therapies.
KKR’s Bae and his co-chief government Scott Nuttall even have private investments within the fund, alongside Druckenmiller, former Goldman Sachs chief government Lloyd Blankfein and Greek basketball star Giannis Antetokounmpo.
Regardless of solely 24 biotechs having listed this 12 months throughout the entire sector, six of Catalio’s corporations, together with Arrivent Biopharma and Septerna Therapeutics, have floated. Catalio was additionally one of many first biotech funds to diversify into personal credit score, launching a fund co-led by Blankfein’s son Jonathan, an government on the agency, that has generated annual returns of greater than 20 per cent, in line with traders.
With Kravis’s steering, Petrocheilos has additionally assembled a “board of advisers” that features main enterprise figures who wouldn’t usually advise such a younger fund. Members embody Alex Gorsky, the previous chief of Johnson & Johnson, and Dina Powell McCormick, an ultra-connected former high Goldman Sachs government who’s now a companion at BDT & MSD.
Petrocheilos predicts Catalio’s future could finally look much more like a non-public fairness agency within the healthcare sector, much like KKR. “We might be open to all that stuff at one level,” stated Petrocheilos. For Kravis, the similarities along with his agency are not possible to overlook: “They remind me of KKR within the early days: we didn’t assume too far out, we simply did offers.”
